Loading page
Loading page
Loading substance route
A notable gap exists between threshold and light dosing ranges, which reflects the limited empirical data available for this novel compound at present.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Assumed to be non-habit-forming based on its similarity to LSD; the desire to use may actually decrease with repeated administration. No formal studies have been conducted.
No evidence of physical dependence potential. Like LSD, 1cP-MiPLA is not associated with withdrawal symptoms or compulsive physical need for the substance.
The LD50 of 1cP-MiPLA is unknown. No formal toxicological studies have been conducted. As a research chemical with limited history of human use, the exact toxic dose remains undetermined.
May act as a potential trigger for psychotic episodes in individuals with underlying psychiatric conditions or family history of mental illness. Adverse psychological reactions including delusions become more likely at higher doses, though severe psychotic episodes requiring medical attention are uncommon with this substance alone.
Seizures are reported rarely and are thought to mainly pose a risk in those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment. Risk is extrapolated from seizures reported following LSD use.
1cP-MiPLA is a novel synthetic lysergamide that first emerged on online research chemical markets around 2020. The compound's origins remain somewhat unclear, with unverified reports attributing its initial synthesis to either Skyler Ulrich or a chemist or group operating under the name Gerstmann.…
Not specifically scheduled, but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act) as an analogue of LSD.
Classified as a schedule I controlled substance under Russian drug control legislation.
Not specifically scheduled under the Controlled Substances Act. However, may be prosecuted as an analogue of LSD under the Federal Analogue Act when intended for human consumption.
Controlled substance as of July 2021. Possession, production, and distribution are prohibited.
Listed as a defined derivative of Lysergic Acid under Verzeichnis E point 263 of the controlled substances ordinance. Exempt when used for scientific or industrial purposes.
8 sources cited